Description of position
We are looking for a Phase1 summer trainee to Computer-Aided Medicine Design (CAMD) group in Espoo. The Phase1 summer trainee will take part in research and method development projects going on in the CAMD group. The Phase1 project can be tailored together and according to the interests and knowledge of the selected candidate. It could be for example molecular machine learning using open DeepChem/MoleculeNet platforms or Structure-Based Drug Design using Molecular Dynamics. The summer job is planned to start in May or June and last for about 3-4 months.
Description of unit
The Computer-Aided Medicine Design (CAMD) group is part of the Global Medicine Design platform that supports all Orion's drug discovery programs. Key responsibilities of Medicine Design include structure design, synthesis design and organic synthesis. CAMD scientists support these tasks by molecular modelling and data analysis methods.
We offer you the opportunity to show your talent in one of the most innovative companies in Finland. We also offer you great colleagues and the opportunity to challenge yourself with interesting tasks. In addition to your own duties, you will get a comprehensive picture of all of Orion's activities and numerous different tasks we have. Welcome to build well-being this summer!
We are looking for a student with >180 credit points from a suitable scientific/technical program. To succeed in this position, the candidate should have knowledge in e.g:
- molecular modeling, e.g. MD simulations of drug-target complexes
- chemometrics, machine learning
Good spoken and written English skills are also required.
Please apply for the position by 10th February!
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,085 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki.